Kedokteran & Kesehatan editorial
Melanoma Management: From Epidemiology to Treatment and Latest Advances
The core problem
Innovation
Why it matters
The discussion highlights the substantial progress in melanoma treatment over the past decade, particularly with the advent of targeted therapies and immunotherapies. However, the review emphasizes that these advances are tempered by challenges: a significant proportion of patients do not respond to immune checkpoint inhibitors, and those who do often develop resistance. Adverse side effects also limit tolerability. The authors argue that understanding the mechanisms of resistance and identifying biomarkers for response are critical for improving patient outcomes.
Nanotechnology offers a promising avenue to address some pharmacological limitations. By encapsulating drugs in nanosystems, it is possible to improve solubility, stability, and targeted delivery, potentially reducing systemic toxicity and enhancing efficacy. The review calls for further research to understand how nanosystems interact with the tumor microenvironment and immune system, and to optimize their design for clinical translation.
Overall, the authors conclude that while melanoma management has evolved significantly, continued innovation in drug development and delivery is essential to further improve survival and quality of life for melanoma patients.
Who should read this
Opening member contentโฆ